Abstract
Analytical treatment interruption (ATI) is the gold standard for validating HIV cure strategies, yet the primary endpoint—the viral setpoint—is often obscured by safety-driven antiretroviral therapy (ART) restart criteria. This study analyzed viral dynamics in 235 participants across three clinical trials to identify reliable surrogate endpoints. The normalized Area Under the Curve (nAUC) emerged as the strongest proxy for the viral setpoint. The findings suggest that an ATI phase exceeding 12 weeks with a confirmed viral load threshold of 100,000 copies/mL for ART restart optimizes the balance between participant safety and data integrity.
The Challenge of Analytical Treatment Interruption
In HIV cure research, the ultimate test of a therapeutic intervention is its ability to maintain viral suppression after the cessation of antiretroviral therapy (ART). This process, known as Analytical Treatment Interruption (ATI), aims to measure the "viral setpoint"—the stable level of viremia reached after the initial rebound.
However, observing the true setpoint presents a significant clinical challenge. To protect participants from the risks associated with high viral loads, trials implement strict restart criteria. If ART is resumed too early (at a conservative threshold), the setpoint is never reached, leaving researchers with insufficient data to judge whether a cure strategy actually works. This creates a fundamental tension between patient safety and the need for high-quality data.
Methodology and Datasets
To resolve this tension, researchers analyzed individual-level viral dynamics data from 235 HIV-infected participants across three distinct clinical trials:
- VRI02 ANRS 149 LIGHT: A Phase II vaccine trial (n=87).
- ANRS/VRI DALIA: A Phase I dendritic cell vaccine trial (n=19).
- ANRS 118 ILIADE: A Phase II/III trial testing IL-2 immunotherapy (n=129).
The study evaluated eleven different virological criteria, categorized into magnitude-related metrics (e.g., peak viral load, setpoint, and nAUC) and time-related metrics (e.g., time to rebound, slope of the rebound). Using Spearman correlations, the team sought to identify which of these easier-to-measure metrics most closely matched the hard-to-measure viral setpoint under various ART restart scenarios.
Key Insights: Identifying the Optimal Proxy
The Failure of Time to Rebound (TTR)
Interestingly, the study found that the time it takes for the virus to become detectable again (TTR) does not correlate well with the eventual setpoint. This suggests that the biological mechanisms triggering the initial viral escape from suppression are distinct from the mechanisms that determine long-term viral control. Consequently, TTR should not be used as a primary indicator of a treatment's ability to maintain a low viral setpoint.
nAUC as the Superior Metric
The normalized Area Under the Curve (nAUC)—which represents the total viral burden over the interruption period—emerged as the most robust predictor of the setpoint. Across the trials, nAUC maintained correlations higher than 0.70 (reaching 0.90 in the ILIADE trial). This makes nAUC an ideal surrogate endpoint for trials where the full setpoint cannot be safely observed.
The "100k" Threshold
A critical finding involves the threshold for restarting ART. Simulations showed that conservative thresholds (e.g., 10,000 or 50,000 copies/mL) significantly weakened the correlation between proxies like nAUC and the actual setpoint. To maintain data integrity, the researchers found that the viral load threshold for restarting ART should be at least 100,000 copies/mL, confirmed by two consecutive measurements. This confirmation step is vital; it prevents premature ART resumption due to transient viral "blips," preserving the statistical power of the trial.
Recommendations for Future Trial Design
Based on these results, the study proposes three key guidelines for the design of HIV cure trials using ATI:
- Duration: The ATI phase should last longer than 12 weeks (ideally up to 24 weeks) to allow viral dynamics to stabilize sufficiently for evaluation.
- Metric: nAUC should be prioritized as a primary or secondary endpoint to capture the magnitude of viral control.
- Restart Criteria: A confirmed threshold of 100,000 copies/mL should be used to balance participant safety with the necessity of capturing enough information to evaluate the intervention.
Limitations and Future Directions
While these findings provide a clear framework for immunotherapy trials, the authors acknowledge that they may not perfectly generalize to all cure strategies, such as passive immunization with neutralizing antibodies. Future work should focus on validating these recommendations across a broader range of interventions and exploring how more frequent monitoring—potentially through home-based testing—could further reduce risks while maintaining high data quality.
Summary updated